CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Vedanta gets $60M to finish Phase 3 for C. diff microbiome therapy

Phase 3Positive
AI Analysis

Summary

Vedanta Biosciences secured $60M in funding to complete Phase 3 development of its C. difficile microbiome therapy, with a readout expected in 2027.

Clinical Trial Data

Phase

Phase 3

Importance:6/10
Sentiment:
0.70
microbiomeC. difficilefundingPhase 3clinical development

Read the original article

Published by Endpoints News on August 6, 2026 11:00 AM

Read Original